Prosecution Insights
Last updated: April 19, 2026

Arrowhead Pharmaceuticals, Inc.

4 pending office actions

Portfolio Summary

4
Total Pending OAs
1
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18181311 RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use SULLIVAN, STEPHANIE LAUREN 1635 Non-Final OA Mar 09, 2023
18178242 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS ZARA, JANE J 1637 Non-Final OA Mar 03, 2023
18074268 RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION ANGELL, JON E 1637 Non-Final OA Dec 02, 2022
18048577 RNAi Agents for Inhibiting Expression of Matrix Metalloproteinase 7 (MMP7), Compositions Thereof, and Methods of Use VANHORN, ABIGAIL LOUISE 1636 Final Rejection Oct 21, 2022

Managing Arrowhead Pharmaceuticals, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month